Mounsif Sara, Setouani Hiba, Nadi Anass, Ghalim Fahd, Delsa Hanane
Gastroenterology and Hepatology, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR.
Cureus. 2022 Dec 3;14(12):e32153. doi: 10.7759/cureus.32153. eCollection 2022 Dec.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) whose management depends on its severity, localization, and course. The coronavirus disease 2019 (COVID-19) pandemic has made the management of this disease more difficult, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) routinely causes respiratory infection, but can also target the gastrointestinal tract. Multiple cases of de novo IBD, IBD flare-ups, and colitis have been associated with COVID-19 infection. We present the case of two patients, with a history of UC, who presented respectively a mild and a severe flare-up of their disease associated with COVID-19 infection. Regardless of recommendations, we decided to optimize the patient's treatment and obtained good clinical, biological, and endoscopic results. This report on the two cases suggests that remaining cautious and optimizing can be a good therapeutic alternative for these patients rather than modifying the treatment.
溃疡性结肠炎（UC）是一种慢性炎症性肠病（IBD），其治疗取决于疾病的严重程度、病变部位和病程。2019年冠状病毒病（COVID-19）大流行使这种疾病的治疗更加困难，因为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）通常会引起呼吸道感染，但也可侵袭胃肠道。多例新发IBD、IBD病情加重及结肠炎与COVID-19感染有关。我们报告了两名有UC病史的患者，他们分别出现了与COVID-19感染相关的轻度和重度疾病发作。尽管有相关建议，但我们决定优化患者的治疗方案，并取得了良好的临床、生物学和内镜检查结果。这两例病例报告表明，保持谨慎并进行优化治疗对这些患者而言可能是比调整治疗更好的选择。
